The Directors have pleasure in presenting the 35th Annual Report of the Company, together with the Auditedaccounts for the financial year ended 31st March’2024.
Particulars
2023-2024
2022-2023
Sales
0
Other Income
19.86
41.93
Total Income
Total Expenses
11.17
19.36
Profit/(Loss)Before Tax
8.69
22.57
Current Year Tax
2.24
Deferred Tax
(0.004)
0.01
Profit/(Loss)After Tax
6.45
22.56
The Company is engaged in the business of pharmaceutical products, drug intermediaries & API’s etc andcould not do any business during the financial year under review. The Board of Directors of your companyare exploring the business opportunities and are confident to start the business in the coming years.
As the Company has not done any business and incurred losses, the Board of Directors has notrecommended any Dividend on the Equity Shares of the Company for the Financial Year ended March 31,2024
Changes in Share Capital
During the year under review, there is no change in Authorized and Paid-up share capital of the Company
Material Changes and Commitments affecting the Financial Position of the Company which haveoccurred between 31st March’2024 and 22nd August’2024 (Date of the Report)
No Material Changes and Commitments affecting the Financial Position of the Company have occurred till22ndAugust’2024
The Company is engaged in the business of business of pharmaceutical products, drug intermediaries & API’setc and there has been no change in the nature of Business of the Company.
During the year under review, the company has not accepted any deposit pursuant to the provisions ofSections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules,2014.
A copy of the Annual Return for the F.Y 2022-23 pursuant to the sub-section (3) of Section 92 of theCompanies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)(a) and is available at the following link: www.venmaxdrugs.com
In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:
i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
ii) The Directors have selected such Accounting Policies and applied them consistently and madejudgements and estimates that were prudent so as to give a true and fair view of the state of affairsof the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Yearunder review.
iii) The Directors have taken proper and sufficient care for the maintenance of adequate accountingrecords in accordance with the provisions of this Act for safeguarding the Assets of the Company andfor preventing and detecting fraud and other irregularities.
iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
v) The Directors had laid down Internal Financial Controls to be followed by the Company and that suchInternal Financial Controls are adequate and were operating effectively.
vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicablelaws and that such system was adequate and operating effectively.
a. Retirement by Rotation:
As per Section 152 of the Companies Act, 2013 and Articles of Association of the Company, Mr. N.Krishnaiah (DIN: 07279009), who retires by rotation at the conclusion of this 35th AGM and offers himself forre-appointment in accordance with the provisions of the Companies Act, 2013. The Directors recommend hisre- appointment.
As on March 31, 2024 the Board constitutes the following directors:
Sl. No.
Name of Director
DIN
Designation
1
Mr. N. Krishnaiah
07279009
Managing Director
2
Dr. A. Ramakrishnaiah
01641977
Independent Director
3
Mrs. Meena Kumari Pilli
00009207
Additional Director (Non-Executive,Independent)
4
Mr. Swapneswar Mishra
10458622
Additional Director (Non-Executive, NIndependent)
During the year Mr. Raj Kumar Rai, Managing Director has resigned from his office w.e.f.16th January2024. The Board accepted his resignation and placed on record for appreciation for his workduring tenure of his office.
Till the date of the Directors’ Report, the following changes took place on the Board/KMP of theCnmnanv:
Sl. No
Name of Director/KMP
Nature ofChange
Date of suchchange
Mr. Dasi Reddy Rakesh
Appointed as AdditionalDirector (Non-Executive,Non-Non-Independent
22/08/2024
Mr. Gundluru Reddappa
Appointed as AdditionalDirector (Non-Executive,Independent)
Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts)Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as ‘Annexure-A’.
Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign ExchangeEarnings or Outflow.
Pursuant to provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment andRemuneration of Managerial Personnel) Rules, 2014 the Company had appointed Mr. Kashinath Sahu,Company Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial AuditReport is annexed herewith as ‘Annexure-B’.
During the year under review, there were no qualifications, reservations or adverse remarks reported bySecretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of hisduties as Secretarial Auditor.
Trading of Equity Shares in BSE under Suspension
The Trading of Equity Shares in BSE is under suspension due to non-payment of Annual Listing Fees. Nowthe Company is in process of making application to the BSE for revocation of suspension.
In compliance with the Regulation 27 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, a separate report on corporate governance along with a certificate from a practicing CompanySecretary on its compliance and forms an integral part of this Board’s Report as “Annexure- C”.
Pursuant to Regulation 34(2)(e) of the SEBI (LODR) Regulations, 2015, Report on Management Discussionand Analysis, is herewith annexed as ‘Annexure-D’
During the year under review, four Meetings of the Board were convened and held, the details of which aregiven in the Corporate Governance Report, which forms part of this report. The intervening gap betweenthe Meetings was within the limits prescribed under the Companies Act, 2013.
Pursuant to the provisions of the Companies Act, 2013 and Regulation 25 of the SEBI (Listing ObligationsAnd Disclosure Requirements) Regulations, 2015, the Board, its Committees and the Directors have carriedout annual evaluation / annual performance evaluation, covering various aspects of the Board’s functioningsuch as adequacy of the composition of the Board and its Committees, Board culture, execution andperformance of specific duties, obligations and governance. The Directors expressed their satisfactionwith the evaluation process.
The Company has received the Declarations from the Independent Directors of the Company to theeffect that they are Meeting the criteria of Independence as provided in sub-section (6) of section 149 ofthe Act and of sub-rule (1) and sub-rule (2) of the Rule 6 of the Companies (Appointment andQualifications of Directors) Rules, 2014.
In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise andexperience (including the proficiency) of the independent directors.
Statutory Auditors
M/s. PPKG & Co, Chartered Accountants (Firm Registration No. 009655S) were appointed as the StatutoryAuditors of the Company at the 34th AGM for a term of 5 consecutive financial year starting from 2023-24to 2027-28 and shall hold office until the conclusion of 38th Annual General Meeting. Your directorsrecommend their appointment.
The Company has an in-house Internal Control System, commensurate with the Size, Scale and Complexityof its Operations. The Scope and Authority of the Internal Audit Function is defined in the Internal AuditManual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairmanof the Audit Committee of the Board and to the Chairman and Management.
The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal ControlSystem in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at alllevels of the Company.
Based on the report of Internal Audit Function, process owners undertake corrective action in their respectiveareas and thereby strengthen the controls. Significant Audit observations and recommendations along withcorrective actions thereon are presented to the Audit Committee of the Board.
The Board has constituted the Audit Committee as per the provisions of Section 177 of the CompaniesAct,2013 and Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The Company Secretary of the Company acts as the Secretary of the Audit Committee. The Composition,Attendance, Powers and Role of the Audit Committee are included in Corporate Governance Report. All therecommendation made by the Audit Committee during the period were accepted by the Board of Directors.
The scope, functions and the terms of reference of the Nomination and Remuneration Committee is inaccordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securitiesand Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. TheComposition, Attendance, Powers and Role of the nomination & Remuneration Committee are included inCorporate Governance Report.
The Composition, Attendance, Powers and Role of the Stakeholders Relationship, Committee are includedin Corporate Governance Report. The Company Secretary of the Company acts as the Secretary of theStakeholders’ Relationship Committee.
The Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertainingto forming of Risk Management Committee, is not applicable to the Company during the Financial Yearunder review.
The Company has not given any Loans nor provided Guarantee nor made any Investments during theFinancial Year 2023-2024, which is beyond the limits as per Section 186 of the Companies Act, 2013.
During the Year, the Company had not entered into any Contract or Arrangement with Related Partieswhich could be considered ‘Material’ according to the Policy of the Company on materiality of RelatedParty Transactions. There were no related party transactions with any person or entity belonging topromoter/ promoter group which holds 10% or more shareholding in the Company. Details of all relatedparty transactions are disclosed in the financial statements.
The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India(Listing obligations and Disclosure Requirements) Regulations, 2015 (“Regulations”) on Preservation of theDocuments of the following type:
(a) documents whose preservation shall be permanent in nature;
(b) documents with preservation period of not less than eight years after completion of the relevanttransactions
The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to theemployees to bring to the attention of the management, the concerns about any unethical behaviorby using the mechanism provided in the Policy. In cases related to financial irregularities, including fraudor suspected fraud, the employees may directly approach the Chairman of the Audit Committee of theCompany. The web link for the policy is as follows: www.venmaxdrugs.com
The Company has adopted a Policy in accordance with the requirements of the Regulation 30 ofSecurities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,2015 (Regulations). The Policy is authorizing the mentioned Key Managerial Personnel for the purpose ofdetermining materiality of an event or information of the Company and to ensure that such informationis adequately disseminated in pursuance with the Regulations and to provide an overall governanceframework for such determination of materiality.
The Company’s remuneration policy is directed towards rewarding performance based on review ofachievements periodically. The remuneration policy is in consonance with the existing industry practice.
The Company’s shareholders may refer the Company’s website for the detailed Nomination & RemunerationPolicy of the Company on the appointment and remuneration of Directors including criteria for determiningqualifications, positive attributes, independence of a Director; and other matters provided under sub¬section (3) of section 178.
The Company has not received any Significant or Material Orders passed by any Regulatory Authority,Court or Tribunal which shall impact the Going Concern Status and Company’s Operations in future.
The Company does not have any Subsidiary, Associate and Joint Venture Companies during the periodunder review.
Employee relations during the period under review continued to be healthy, cordial and harmonious at alllevels and your Company is committed to maintain good relations with the employees. It has taken varioussteps to improve productivity across the organization.
Business Risk Evaluation and Management is an ongoing process within the Organization. The Companyhas a robust Risk Management Framework to identify, monitor and minimize risks as also identify businessopportunities. At present, the Company has not identified any element of risk which may threaten theexistence of the Company.
Your Company does not have any Unpaid or Unclaimed amounts/Securities lying for a period of seven years.Therefore, there were no Funds/Securities which were required to be transferred to Investor Educationand Protection Fund (IEPF).
In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules,2014, the Company does not have any Employee who is employed throughout the Financial Year and inreceipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year andin receipt of Rs.8.50 Lakhs or more per month.
The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility arenot applicable to our Company
The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are notapplicable to the Company.
Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI(Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Code of Conduct forprevention of Insider Trading and the Code for Corporate Disclosures (“Code”), as approved by the Boardfrom time to time, are in force by the Company. The objective of this Code is to protect the interest ofShareholders at large, to prevent misuse of any price sensitive information and to prevent any InsiderTrading activity by dealing in Shares of the Company by its Directors, Designated Employees and otherEmployees. The Company also adopts the concept of Trading Window Closure, to prevent its Directors,Officers, Designated Employees and other Employees from Trading in the Securities of VENMAX DRUGS ANDPHARMACEUTICALS LIMITED at the time, when there is Unpublished Price Sensitive Information.
In order to prevent Sexual Harassment of Women at Workplace as per “The Sexual Harassment of Womenat Workplace (Prevention, Prohibition and Redressal) Act, 2013” has been notified. Under the said Act,every Company is required to set up an Internal Complaints Committee to look into complaints relating toSexual Harassment at workplace of any women employee. As required under law, an Internal ComplianceCommittee has been constituted for reporting and conducting inquiry into the complaints made by thevictim on the harassments at the workplace. During the Year under review, no complaint of harassment atthe workplace was received by the Committee.
Your directors take this opportunity to place on record the valuable co-operation and continuous supportextended by its valued business associates, Consultants, Auditors, Suppliers, Customers, Banks / FinancialInstitutions, Government authorities and the shareholders for their continuously reposed confidence in theCompany and look forward to having the same support in all its future endeavors.
Your directors also wish to place on record their sincere appreciation for significant contribution made bythe employees at all the levels through their dedication, hard work and commitment, thereby enabling theCompany to boost its performance during the year under report.
Place: Hyderabad
Sd/- Sd/-
N. Krishnaiah P. Meena Kumari
Managing Director Director
(DIN: 07279009) (DIN: 10458622)